Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome.

Kanne, Anna-Maria; Jülich, Maike; Mahmutovic, Amira; Tröster, Isabella; Sehnert, Bettina; Urbonaviciute, Vilma; Voll, Reinhard E; Kollert, Florian Kim (2018). Association of High Mobility Group Box Chromosomal Protein 1 and Receptor for Advanced Glycation End Products Serum Concentrations With Extraglandular Involvement and Disease Activity in Sjögren's Syndrome. Arthritis care & research, 70(6), pp. 944-948. Wiley 10.1002/acr.23420

[img] Text
Kanne_et_al-2018-Arthritis_Care_&_Research.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (112kB) | Request a copy

OBJECTIVE

To assess serum levels of high mobility group box chromosomal protein 1 (HMGB-1) and the soluble receptor for advanced glycation end products (sRAGE) in patients with Sjögren's syndrome (SS) and explore correlations with disease activity.

METHODS

Thirty-nine patients with SS and 21 healthy controls were included in this cross-sectional study. Clinical and laboratory values were obtained from all patients. Disease activity was assessed using the European League Against Rheumatism SS Disease Activity Index (ESSDAI). Serum samples were collected and HMGB-1 and sRAGE levels were measured using enzyme-linked immunosorbent assay (ELISA), and HMGB-1 concentrations were semiquantified by Western blotting.

RESULTS

In ELISA, HMGB-1 serum levels did not differ between healthy controls and patients with SS (P = 0.783). When measured by semiquantitative Western blotting, HMGB-1 levels were increased in patients with SS compared to healthy controls (P = 0.012). HMGB-1 serum levels detected by Western blotting were higher in patients with extraglandular manifestations (P = 0.003) and were correlated with ESSDAI disease activity (r = 0.544, P < 0.0001). Furthermore, sRAGE was elevated in the sera of patients with SS (P = 0.003) compared to healthy controls and was also correlated with the ESSDAI (r = 0.545, P = 0.002).

CONCLUSION

Serum levels of total HMGB-1 and sRAGE were elevated in patients with SS compared to healthy controls and correlated with disease activity as measured by the ESSDAI. Patients with extraglandular involvement had high serum levels of HMGB-1.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Kollert, Florian Kim

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2151-4658

Publisher:

Wiley

Language:

English

Submitter:

Burkhard Möller

Date Deposited:

26 Jul 2019 08:28

Last Modified:

23 Oct 2019 15:52

Publisher DOI:

10.1002/acr.23420

PubMed ID:

28941024

BORIS DOI:

10.7892/boris.125143

URI:

https://boris.unibe.ch/id/eprint/125143

Actions (login required)

Edit item Edit item
Provide Feedback